Cargando…
Subcutaneous allergen immunotherapy for asthma: A randomized, double-blind, placebo-controlled study with a standardized Blomia tropicalis vaccine
BACKGROUND: Sensitization to Blomia tropicalis (Bt) is very frequent in the tropics, and particularly in Cuba, being a significant cause of allergic asthma. Allergen immunotherapy (AIT) with Bt can be a therapeutic option, however, placebo-controlled clinical trials have not been reported. OBJECTIVE...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155230/ https://www.ncbi.nlm.nih.gov/pubmed/32308779 http://dx.doi.org/10.1016/j.waojou.2020.100098 |
_version_ | 1783521989305040896 |
---|---|
author | Castro-Almarales, Raúl Lázaro Ronquillo-Díaz, Mercedes Álvarez-Castelló, Mirta Rodríguez-Canosa, José González-León, Mayda Enríquez-Domínguez, Irene Navarro-Viltre, Bárbara Ivonne Mateo-Morejón, Maytee Oliva-Díaz, Yunia Ramírez-González, Wendy Cox, Linda Labrada-Rosado, Alexis |
author_facet | Castro-Almarales, Raúl Lázaro Ronquillo-Díaz, Mercedes Álvarez-Castelló, Mirta Rodríguez-Canosa, José González-León, Mayda Enríquez-Domínguez, Irene Navarro-Viltre, Bárbara Ivonne Mateo-Morejón, Maytee Oliva-Díaz, Yunia Ramírez-González, Wendy Cox, Linda Labrada-Rosado, Alexis |
author_sort | Castro-Almarales, Raúl Lázaro |
collection | PubMed |
description | BACKGROUND: Sensitization to Blomia tropicalis (Bt) is very frequent in the tropics, and particularly in Cuba, being a significant cause of allergic asthma. Allergen immunotherapy (AIT) with Bt can be a therapeutic option, however, placebo-controlled clinical trials have not been reported. OBJECTIVE: To assess the therapeutic effect and safety of AIT for asthma using a standardized allergen vaccine of B. tropicalis by subcutaneous route, in allergic asthmatic patients exposed and sensitized to this mite species. METHODS: A double-blind, placebo-controlled Phase II trial was conducted in 35 adults (18 with treatment and 17 with placebo), with mild to moderate asthma, predominantly sensitized to Bt. AIT was administered subcutaneously in increasing doses from 4 to 6000 Biological Units using a locally manufactured standardized extract (BIOCEN, Cuba). Patient assessment was performed using symptom-medication score (SMS), peak expiratory flow and skin reactivity relative to Histamine as measured by skin prick test (SPT). RESULTS: The 12-month treatment achieved a significant (p < 0.001) decrease of SMS. Symptom score showed only 41% (CI: 26–61) of placebo values, whereas medication was 34.5% (22.4%–63.3%). Treatment was regarded clinically effective in 67% of patients (OR 32; 95%CI: 17 to 102). The effect size on symptoms and medication was higher than has been reported with equivalent allergen dosages of D. pteronyssinus and D. siboney in Cuban asthmatic patients. Skin reactivity to Bt was also significantly reduced (p = 0.0001), increasing 148-fold the allergen threshold to elicit a positive skin test. This desensitization effect was specific to Bt and did not modify the reactivity to Dermatophagoides. The change of specific skin reactivity was significantly (p < 0.05) correlated to clinical improvement. All adverse events were local with a frequency of 2.4% of injections. CONCLUSIONS: Subcutaneous AIT with Blomia tropicalis was effective and safe in asthmatic adults exposed and sensitized to this mite species in a tropical environment. TRIAL REGISTRATION: Cuban Public Registry of Clinical Trials: RPCEC00000026 (WHO International Clinical Trial Registry Platform ICTRP). |
format | Online Article Text |
id | pubmed-7155230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | World Allergy Organization |
record_format | MEDLINE/PubMed |
spelling | pubmed-71552302020-04-17 Subcutaneous allergen immunotherapy for asthma: A randomized, double-blind, placebo-controlled study with a standardized Blomia tropicalis vaccine Castro-Almarales, Raúl Lázaro Ronquillo-Díaz, Mercedes Álvarez-Castelló, Mirta Rodríguez-Canosa, José González-León, Mayda Enríquez-Domínguez, Irene Navarro-Viltre, Bárbara Ivonne Mateo-Morejón, Maytee Oliva-Díaz, Yunia Ramírez-González, Wendy Cox, Linda Labrada-Rosado, Alexis World Allergy Organ J Article BACKGROUND: Sensitization to Blomia tropicalis (Bt) is very frequent in the tropics, and particularly in Cuba, being a significant cause of allergic asthma. Allergen immunotherapy (AIT) with Bt can be a therapeutic option, however, placebo-controlled clinical trials have not been reported. OBJECTIVE: To assess the therapeutic effect and safety of AIT for asthma using a standardized allergen vaccine of B. tropicalis by subcutaneous route, in allergic asthmatic patients exposed and sensitized to this mite species. METHODS: A double-blind, placebo-controlled Phase II trial was conducted in 35 adults (18 with treatment and 17 with placebo), with mild to moderate asthma, predominantly sensitized to Bt. AIT was administered subcutaneously in increasing doses from 4 to 6000 Biological Units using a locally manufactured standardized extract (BIOCEN, Cuba). Patient assessment was performed using symptom-medication score (SMS), peak expiratory flow and skin reactivity relative to Histamine as measured by skin prick test (SPT). RESULTS: The 12-month treatment achieved a significant (p < 0.001) decrease of SMS. Symptom score showed only 41% (CI: 26–61) of placebo values, whereas medication was 34.5% (22.4%–63.3%). Treatment was regarded clinically effective in 67% of patients (OR 32; 95%CI: 17 to 102). The effect size on symptoms and medication was higher than has been reported with equivalent allergen dosages of D. pteronyssinus and D. siboney in Cuban asthmatic patients. Skin reactivity to Bt was also significantly reduced (p = 0.0001), increasing 148-fold the allergen threshold to elicit a positive skin test. This desensitization effect was specific to Bt and did not modify the reactivity to Dermatophagoides. The change of specific skin reactivity was significantly (p < 0.05) correlated to clinical improvement. All adverse events were local with a frequency of 2.4% of injections. CONCLUSIONS: Subcutaneous AIT with Blomia tropicalis was effective and safe in asthmatic adults exposed and sensitized to this mite species in a tropical environment. TRIAL REGISTRATION: Cuban Public Registry of Clinical Trials: RPCEC00000026 (WHO International Clinical Trial Registry Platform ICTRP). World Allergy Organization 2020-04-10 /pmc/articles/PMC7155230/ /pubmed/32308779 http://dx.doi.org/10.1016/j.waojou.2020.100098 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Castro-Almarales, Raúl Lázaro Ronquillo-Díaz, Mercedes Álvarez-Castelló, Mirta Rodríguez-Canosa, José González-León, Mayda Enríquez-Domínguez, Irene Navarro-Viltre, Bárbara Ivonne Mateo-Morejón, Maytee Oliva-Díaz, Yunia Ramírez-González, Wendy Cox, Linda Labrada-Rosado, Alexis Subcutaneous allergen immunotherapy for asthma: A randomized, double-blind, placebo-controlled study with a standardized Blomia tropicalis vaccine |
title | Subcutaneous allergen immunotherapy for asthma: A randomized, double-blind, placebo-controlled study with a standardized Blomia tropicalis vaccine |
title_full | Subcutaneous allergen immunotherapy for asthma: A randomized, double-blind, placebo-controlled study with a standardized Blomia tropicalis vaccine |
title_fullStr | Subcutaneous allergen immunotherapy for asthma: A randomized, double-blind, placebo-controlled study with a standardized Blomia tropicalis vaccine |
title_full_unstemmed | Subcutaneous allergen immunotherapy for asthma: A randomized, double-blind, placebo-controlled study with a standardized Blomia tropicalis vaccine |
title_short | Subcutaneous allergen immunotherapy for asthma: A randomized, double-blind, placebo-controlled study with a standardized Blomia tropicalis vaccine |
title_sort | subcutaneous allergen immunotherapy for asthma: a randomized, double-blind, placebo-controlled study with a standardized blomia tropicalis vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155230/ https://www.ncbi.nlm.nih.gov/pubmed/32308779 http://dx.doi.org/10.1016/j.waojou.2020.100098 |
work_keys_str_mv | AT castroalmaralesraullazaro subcutaneousallergenimmunotherapyforasthmaarandomizeddoubleblindplacebocontrolledstudywithastandardizedblomiatropicalisvaccine AT ronquillodiazmercedes subcutaneousallergenimmunotherapyforasthmaarandomizeddoubleblindplacebocontrolledstudywithastandardizedblomiatropicalisvaccine AT alvarezcastellomirta subcutaneousallergenimmunotherapyforasthmaarandomizeddoubleblindplacebocontrolledstudywithastandardizedblomiatropicalisvaccine AT rodriguezcanosajose subcutaneousallergenimmunotherapyforasthmaarandomizeddoubleblindplacebocontrolledstudywithastandardizedblomiatropicalisvaccine AT gonzalezleonmayda subcutaneousallergenimmunotherapyforasthmaarandomizeddoubleblindplacebocontrolledstudywithastandardizedblomiatropicalisvaccine AT enriquezdominguezirene subcutaneousallergenimmunotherapyforasthmaarandomizeddoubleblindplacebocontrolledstudywithastandardizedblomiatropicalisvaccine AT navarroviltrebarbaraivonne subcutaneousallergenimmunotherapyforasthmaarandomizeddoubleblindplacebocontrolledstudywithastandardizedblomiatropicalisvaccine AT mateomorejonmaytee subcutaneousallergenimmunotherapyforasthmaarandomizeddoubleblindplacebocontrolledstudywithastandardizedblomiatropicalisvaccine AT olivadiazyunia subcutaneousallergenimmunotherapyforasthmaarandomizeddoubleblindplacebocontrolledstudywithastandardizedblomiatropicalisvaccine AT ramirezgonzalezwendy subcutaneousallergenimmunotherapyforasthmaarandomizeddoubleblindplacebocontrolledstudywithastandardizedblomiatropicalisvaccine AT coxlinda subcutaneousallergenimmunotherapyforasthmaarandomizeddoubleblindplacebocontrolledstudywithastandardizedblomiatropicalisvaccine AT labradarosadoalexis subcutaneousallergenimmunotherapyforasthmaarandomizeddoubleblindplacebocontrolledstudywithastandardizedblomiatropicalisvaccine |